
YmAbs’ 131I-8H9 Receives EU Orphan Drug Designation 03 March 2017
Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation NEW YORK, March 1, 2017 –... Read more
Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation NEW YORK, March 1, 2017 –... Read more
Indstillingsskema Novo Nordisk Fondens Gymnasielærerpris 2017 Opslag Novo Nordisk Fondens Gymnasielærerpris... Read more
7 principper for sundhedsdata >>
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive... Read more
Y-mAbs Therapeutics, Inc. closes $12 million in private placement among current shareholders NEW YORK,... Read more
Det danske biotekselskab Minervax melder om positive resultater fra et fase 1-forsøg med dets vaccine... Read more
IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory... Read more
Join us in New York to meet with top investors, pharma & partners hosted at Citi Headquarters. -Special... Read more
Novo Nordisk Fondens Gymnasielærerpris blev indstiftet i 2014 af DANISH BIO – DANSK BIOTEK og ... Read more